Non-proportional hazards in immuno-oncology: Is an old perspective needed?

被引:14
作者
Magirr, Dominic [1 ]
机构
[1] Novartis Pharma AG, Adv Methodol & Data Sci, Basel, Switzerland
关键词
drug regulation; immuno‐ oncology; log‐ rank test; nonproportional hazards; SURVIVAL-DATA; RANK TEST; TESTS; LOGRANK; EQUIVALENCE; RATIO;
D O I
10.1002/pst.2091
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A fundamental concept in two-arm non-parametric survival analysis is the comparison of observed versus expected numbers of events on one of the treatment arms (the choice of which arm is arbitrary), where the expectation is taken assuming that the true survival curves in the two arms are identical. This concept is at the heart of the counting-process theory that provides a rigorous basis for methods such as the log-rank test. It is natural, therefore, to maintain this perspective when extending the log-rank test to deal with non-proportional hazards, for example, by considering a weighted sum of the "observed - expected" terms, where larger weights are given to time periods where the hazard ratio is expected to favor the experimental treatment. In doing so, however, one may stumble across some rather subtle issues, related to difficulties in the interpretation of hazard ratios, that may lead to strange conclusions. An alternative approach is to view non-parametric survival comparisons as permutation tests. With this perspective, one can easily improve on the efficiency of the log-rank test, while thoroughly controlling the false positive rate. In particular, for the field of immuno-oncology, where researchers often anticipate a delayed treatment effect, sample sizes could be substantially reduced without loss of power.
引用
收藏
页码:512 / 527
页数:16
相关论文
共 41 条
  • [31] Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyzeRCTsin oncology
    Ristl, Robin
    Ballarini, Nicolas M.
    Goette, Heiko
    Schueler, Armin
    Posch, Martin
    Koenig, Franz
    [J]. PHARMACEUTICAL STATISTICS, 2021, 20 (01) : 129 - 145
  • [32] Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group
    Roychoudhury, Satrajit
    Anderson, Keaven M.
    Ye, Jiabu
    Mukhopadhyay, Pralay
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (02): : 280 - 294
  • [33] A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome
    Royston, Patrick
    Parmar, Mahesh K. B.
    [J]. TRIALS, 2020, 21 (01)
  • [34] Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
    Royston, Patrick
    Parmar, Mahesh K. B.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2013, 13
  • [35] Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond
    Rufibach, Kaspar
    [J]. PHARMACEUTICAL STATISTICS, 2019, 18 (02) : 145 - 165
  • [36] Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations
    Tian, Lu
    Fu, Haoda
    Ruberg, Stephen J.
    Uno, Hajime
    Wei, Lee-Jen
    [J]. BIOMETRICS, 2018, 74 (02) : 694 - 702
  • [37] Is the Log-Rank and Hazard Ratio Test/Estimation the Best Approach for Primary Analysis for All Trials?
    Uno, Hajime
    Tian, Lu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (17) : 2000 - +
  • [38] Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
    Uno, Hajime
    Claggett, Brian
    Tian, Lu
    Inoue, Eisuke
    Gallo, Paul
    Miyata, Toshio
    Schrag, Deborah
    Takeuchi, Masahiro
    Uyama, Yoshiaki
    Zhao, Lihui
    Skali, Hicham
    Solomon, Scott
    Jacobus, Susanna
    Hughes, Michael
    Packer, Milton
    Wei, Lee-Jen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (22) : 2380 - U138
  • [39] WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269
  • [40] Xu R, 2000, Biostatistics, V1, P423, DOI 10.1093/biostatistics/1.4.423